Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: Roche
New Personalized Medicine Increases Survival in Melanoma Patients
Metastatic melanoma is the deadliest and most aggressive from of skin cancer. A person with metastatic melanoma typically has a short life expectancy that is measured in months. The mainstay treatments for metastatic melanoma are dacarbazine (DTIC), interleukin-2 (IL-2) and … Continue reading →
Posted in Cancer, Melanoma
|
Tagged BRAF V600 mutation, dacarbazine, DTIC, Genentech, IFN, IL-2, interferon, interleukin-2, Melanoma, Metastatic melanoma, Patient Access Program, progression-free survival, RG7204, Roche, Survival
|
Comments Off on New Personalized Medicine Increases Survival in Melanoma Patients
FDA Approves Halaven for Late-Stage Breast Cancer
Good news for patients with late stage metastatic breast cancer. The US Food and Drug Administration (FDA) approved eribulin mesylate injection (Halaven; Eisai, Inc) for the treatment of metastatic breast cancer in patients who have received at least 2 prior … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged anthracycline, Bristol-Myers Squibb, capecitabine, chemotherapy, Eisai, eribulin, Halaven, ixabepilone, Ixempra, Metastatic breast cancer, paclitaxel, resistant, Roche, Survival, taxane, Xeloda
|
Comments Off on FDA Approves Halaven for Late-Stage Breast Cancer
